Patients, Not Patents, Will Shape Life Science

Why M&A strategy focusing on selling low-margin business inhibits innovation, lowers entry barriers, dilutes expertise, and weakens patient ties In the last years, Mergers and Acquisitions strategies in life science have reflected the desire of large organizations to adapt to changing market conditions and to focus on areas with a higher potential for size and profit growth. To increase shareholder value, pharmaceutical companies have expanded into precision medicine, oncology, cell and gene therapies, and other high-potential fields. Generally speaking, they adopted a well-oiled two-step approach:  A divestment of their over-the-counter (OTC) and generic divisions, which are typically lower-margin and less innovative…...